Buyer’s Guide: Collateral Management & OTC Derivatives Processing Solutions 2019

• Vendor Selection & Total Cost of Ownership – Which vendor solution is capable of offering a ‘true,’ front-to-back, single-platform experience at an enterprise-wide level, thus negating the need for costly, labour-intensive deployments and implementations of two or more systems? and
• Modularity & Buy-and-Build – From a product or technology architecture perspective, which solution is modular-enough to allow an investment bank to pluck out specific components of a vendor offering that can then be married with existing, in-house built, legacy middle- or back-office systems that are often near-impossible to displace?

Underlying those two questions is the reality that investment bank vendor solutions implementations in 2019 typically remain on-premises installs that can range in cost between USD 100m and USD 200m over one-two years to execute effectively.

However, the persistent complexity of the other bank systems that must interface with a collateral management or OTC derivatives processing solution from the front-office into the back-office means that the avoidance of anything less than a traditional on-premises install remains a challenging prospect for vendors and their sellside customers.

For this report, GreySpark Partners surveyed six of the leading vendors that provide investment banks and other financial markets institutions with both collateral management and OTC derivatives processing solutions on a full-stack basis:

• Calypso (Collateral Management & OTC Derivatives Processing);
• Finastra Fusion Market (OTC Derivatives Processing only);
• FIS APEX Collateral & Front Arena (Collateral Management & OTC Derivatives Processing, respectively);
• IHS Markit Collateral Manager & Portfolio Manager / MarkitSERV / thinkFolio / EDM (Collateral Management & OTC Derivatives Processing, respectively); and
• Murex3 (Collateral Management & OTC Derivatives Processing)
• Nomura Research Institute (NRI) GX Margins & GX Derivs (Collateral Management & OTC Derivatives Processing, respectively).